Comparative Effectiveness and Safety of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome: A Retrospective Cohort Analysis

ConclusionIn this population ‐based cohort of incident ACS patients, ticagrelor was associated with a reduced rate of recurrent nonfatal CVD events and major and minor bleeding events compared with prasugrel.This article is protected by copyright. All rights reserved.

Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 21, 2019 Category: Drugs & Pharmacology Authors: Ghadeer K. Dawwas, Erich Dietrich, David Winchester, Almut G. Winterstein, Rich Segal, Haesuk Park Tags: Original Research Article Source Type: research